Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors

Cancer Research

Volumn 48, Issue 17, 1988, Pages 5011-5016

  Yoshida, Seiichi ^a   Tanaka, Ryuichi ^a   Takai, Nobuyuki ^a   Ono, Kohji ^a  

^a NIIGATA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2;

ADOPTIVE TRANSFER; BRAIN TUMOR; CLINICAL ARTICLE; GLIOMA; HUMAN; IMMUNOTHERAPY; INTRATUMORAL DRUG ADMINISTRATION; LYMPHOKINE ACTIVATED KILLER CELL; PRIORITY JOURNAL;

ADOLESCENT; ADULT; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GLIOMA; HEMATOPOIETIC STEM CELLS; HUMAN; IMMUNIZATION, PASSIVE; INTERLEUKIN-2; KILLER CELLS; MALE; MIDDLE AGE; PHENOTYPE; RECOMBINANT PROTEINS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0023758637     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Lotze, M. T., Grim, E. A., Mazumder, A., Strausser, J. L., and Rosenberg, S. A. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res., 41:4420-4425, 1981.
2. Morgan, D. A., Ruscelli, F. W., and Gallo, R. Selective in vitro growth of Tlymphocytes from normal human bone marrows. Science (Wash. DC), 193:1007-1008, 1976.
3. Aarden, L. A. Revised nomenclature for antigen-nonspecific T-cell proliferation and helper factors. J. Immunol., 123: 2928-2929, 1979.
4. Lotze, M. T., Grimm, E. A., Mazumder, A., Strausser, J. L., and Rosenberg, S. A. In vitro growth of cytotoxic human lymphocytes. IV. Lysis of fresh and cultured autologous tumor by lymphocytes cultured in T-cell growth factor (TCGF). Cancer Res., 41:4420-4425, 1981.
5. Rosenberg, S. A. The adoptive immunotherapy of cancer: Accomplishments and prospects. Cancer Treat. Rep., 68: 233-255, 1984.
6. Böyum, A. Separation of leucocytes from blood and bone marrow. Scand. J. Clin. Lab. Invest., 21 (Suppl. 97): 1, 1968.
7. Shapiro, J. R., Yung, W. K. A., and Shapiro, W. R. Isolation, karyotype, and clonal growth of heterogeneous subpopulations of human malignant gliomas. Cancer Res., 41: 2349-2359, 1981.
8. Grimm, E. A., Mazumder, A., and Rosenberg, S. A. In vitro growth of cytotoxic human lymphocytes. V. Generation of allospecific cytotoxic lymphocytes to nonimmunogenic antigen by cellular immune supplementation at in vitro sensitization with partially purified TCGF. Cell. Immunol. 70:248-259, 1982.
9. Yoshida, S., Takai, N., and Tanaka, R. Functional analysis of interleukin-2 in immune surveillance against brain tumors. Neurosurgery, 21: 627-629, 1987.
10. Grimm, E. A., Mazumder, A., Zhang, H. Z., and Rosenberg, S. A. The lymphokine activated killer cell phenomenon: Lysis of NK resistant fresh solid tumor cells by IL-2 activated autologous human peripheral blood lymphocyte. J. Exp. Med., 755:1823-1841, 1982.
11. Rosenstein, M., Yron, L., Kaufmann, Y., and Rosenberg, S. A. Lymphokine activated killer cells: Lysis of fresh syngeneic NK-resistant murine tumor cells by lymphocyte cultured in interleukin-2. Cancer Res., 44: 1946-1953, 1984.
12. Mazumder, A., Grimm, E. A., and Rosenberg, S. A. Characterization of the lysis of fresh human solid tumors by autologous lymphocytes activated in vitro with phytohemagglutinin. J. Immunol., 130: 958-964, 1983.
13. Tanaka, R., and Sobue, H. Immunity of the brain tumor: Immunological specificity of the brain. Brain Nerve (Tokyo), 35:451-459, 1983.
14. Yoshida, S., Hari, N., Takai, N., and Tanaka, R. Immunological values of the measurements of IgG-FcR(+) i -cells in patients with malignant brain tumors. Brain Nerve (Tokyo), 37:1073-1078, 1985.
15. Yoshida, S. Immunosuppressive mechanism in patients with malignant brain tumors. Brain Nerve (Tokyo), 37: 1137-1143, 1985.
16. Kadisch, A. S., and Tansey, F. A. Interferon as a mediator of human lymphocyte suppression. J. Exp. Med., 151: 637-650, 1980.
17. Takaku, F. Interleukin; clinical immunology. Rinsho Meneki, 18 (Suppl. 10): 112-121, 1986.
18. Cheever, M. A., Greenberg, P. D., and Fater, A. Specific adoptive therapy of established leukemia with syngeneic lymphocytes sequentially immunized in vivo and in vitro and nonspecifically expanded by culture with interleukin 2. J. Immunol., 126: 1318-1322, 1981.
19. Mills, G. B., Carlson, G., and Paetkau, V. Generation of cytotoxic lympho cytes to syngeneic tumors by using co-stimulator (interleukin 2): In vivo activity. J. Immunol., 725: 1904-1909, 1980.
20. Bakacs, T., Gergely, P., and Klein, E. Characterization of cytotoxic human T-lymphocyte subpopulations: The role of Fc receptor carrying cells. Cell. Immunol., 32: 317-328, 1977.
21. Bolhuis, R. L. H., Schuit, H. R. E., Nooyen, A. M., and Ronteltap, C. P. M. Characterization of natural killer (NK) cells and killer (K) cells in human blood: Discrimination between NK and K cell activities. Eur. J. Immunol., 8:731-740, 1978.
22. Kaplan, J., and Callevaret, D. Expression of human T-lymphocyte antigens by natural killer cells. J. Natl. Cancer Inst., 60: 961-964, 1978.
23. Ortaldo, J. R., Bonnard, G. D., and Herberman, R. B. Cytotoxic reactivity of human lymphocytes cultured in vitro. J. Immunol., 119:1351-1357,1977.
24. Seeley, J. K., and Golub, S. H. Studies on cytotoxicity generated in human mixed lymphocyte cultures. I. Time course and target spectrum of several distinct concomitant cytotoxic activities. J. Immunol., 720:1415-1422,1978.
25. Masucci, M. G., Klein, E., and Argov, S. Disappearance of the NK effect after explanation of lymphocytes and generation of similar nonspecific cytotoxicity correlated to the level of blastogenesis in activated cultures. J. Immunol., 124: 2458-2463, 1980.
26. Koide, Y., and Takasugi, M. Augmentation of human natural cell-mediated cytotoxicity by a soluble factor. I. Production of N-cell-activating factor (NAF). J. Immunol., 121:872-879, 1978.
27. Hunninghake, G. W., and Fauci, A. S. Lymphocyte-mediated cytotoxicity against human allogeneic and autologous lymphoid targets after concanavalin A-activation of cytotoxic effector cells. J. Immunol., 119:1122-1128,1977.
28. Zarling, J. M., and Bach, F. H. Continuous culture of T cells cytotoxic for autologous human leukemia cells. Nature (Lond.). 280: 685-688, 1979.
29. Lotze, M. T., Line, B. R., Mathisen, D. J., and Rosenberg, S. A. The in vivo distribution of autologous human and murine lymphoid cells grown in T-cell growth factor (TCGF): Implications for the adoptive immunotherapy of tumors. J. Immunol., 125: 1487-1493, 1980.
30. Eberlein, T. J., Rosenstein, M., Spiess, P., Wesley, R., and Rosenberg, S. A. Adoptive chemoimmunotherapy of a asyngeneic murine lymphoma with long-term lymphoid cell lines expanded in T-cell growth factor. Cancer Immunol. Immunother., 13: 5-13, 1982.
31. Fernandez-Cruz, E., Gilman, S. C., and Feldman, J. D. Immunotherapy of a chemically-induced sarcoma in rats: Characterization of the effector T-cell subunitsand nature of suppression. J. Immunol., 128: 1112-1117, 1982.
32. Kedar, E., Ikejiri, B. L., Gorelik, E., and Herberman, R. B. Natural cell mediated cytotoxicity in vitro and inhibition of tumor growth in vivo by murine lymphoid cells cultured with T-cell growth factor (TCGF). Cancer Immunol. Immunother., 13: 14-23, 1982.
33. Kan, N., Inamoto, T., Hori, Y., Nio, Y., and Tobe, R. Adoptive immuno therapy to the malignant tumors. J. Jpn. Soc. Cancer Ther. (Kyoto), 20: 784-796, 1985.